A Case of Periprocedural Discontinuation of Apixaban Resulting in Intra-aortic Thrombosis

Abstract

Apixaban, a novel oral anticoagulant is approved for anticoagulation in non-valvular atrial fibrillation. Apixaban is found to be superior to warfarin in prevention of stroke and thromboembolism and is associated with lesser risk of bleeding. Peri-procedural discontinuation of apixaban is safe, but the risk of thrombosis exists. We here present a case of arterial thrombosis that lead to lower limb ischemia upon periprocedural discontinuation of apixaban.